{"id":"pfizer-pcv13","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site erythema"},{"rate":"15-25","effect":"Injection site swelling"},{"rate":"10-15","effect":"Fever"},{"rate":"50-80","effect":"Irritability"},{"rate":"30-40","effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsules from 13 different pneumococcal serotypes conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease, pneumonia, and other pneumococcal infections caused by these serotypes.","oneSentence":"PCV13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:24.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of pneumococcal pneumonia and otitis media in pediatric populations"}]},"trialDetails":[{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT03619252","phase":"PHASE4","title":"Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents","status":"COMPLETED","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2018-07-01","conditions":"Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia","enrollment":36},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT01908283","phase":"PHASE4","title":"Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Klara M. Pósfay Barbe","startDate":"2014-03","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":300},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT01577771","phase":"PHASE4","title":"Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso","status":"COMPLETED","sponsor":"Agence de Médecine Préventive, France","startDate":"2013-02","conditions":"Pneumococcal Infections","enrollment":663}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":623,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pfizer PCV13","genericName":"Pfizer PCV13","companyName":"Walvax Biotechnology Co., Ltd.","companyId":"walvax-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"PCV13 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and otitis media in pediatric populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}